...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: USA ZHCLF investors

"Question 1: How did I receive Zenith Capital Corp. (“Zenith” or the “Company”) common shares?

Answer: Many of Zenith’s shareholders received shares of the Company as a result of the spin out by Resverlogix Corp. (TSX: RVX) on June 3, 2013. At the time of the spin out, Resverlogix shareholders received one share of Zenith Epigenetics Corp. for every Resverlogix share held with no additional cash outlay. Zenith Epigenetics Corp. subsequently changed its name to Zenith Capital Corp."

Note the name change.

Koo

 

Share
New Message
Please login to post a reply